Eric Richman | Source | CEO at Gain Therapeutics

ER

Eric Richman

CEO at Gain Therapeutics and 2 other companies
On the record
Share profile 
Link:
Bio
Edit

Eric I. Richman began his career in venture capital at HealthCare Ventures and most recently was venture partner at Brace Pharma Capital, a life science venture capital firm. He also serves as an advisor to Broad Oak Capital, a life science private equity firm and as a Venture Partner at Allele Capital. Mr. Richman has also previously served as chief executive officer of Tyrogenex and PharmAthene, subsequently acquired by Altimmune.

Employment
Sign up to view all
Media
Sign up to view all
  • STAR Candidates Boost GCase in Cell, Animal Models

    Gain Therapeutics' investigational compounds were able to lessen motor symptoms in a rat model of GBA1-associated Parkinson's disease and also decrease the levels of alpha-synuclein accumulation in nerve cells — two hallmarks of the neurodegenerative disease. The two candidates — GT-02287 and...

    Article
Recent Quotes
Sign up to view all

  • We identified two STAR lead candidates that have the potential to help Parkinson’s patients with GBA1 gene mutations as well as patients whose GCase protein is misfolded due to aging cellular processes.